XML 33 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies
12 Months Ended
Oct. 02, 2020
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies COMMITMENTS AND CONTINGENCIES
Indemnification Agreements
In conjunction with the sale of the Company’s products in the ordinary course of business, the Company provides standard indemnification of business partners and customers for losses suffered or incurred for property damages, death and injury and for patent, copyright or any other intellectual property infringement claims by any third parties with respect to its products. The terms of these indemnification arrangements are generally perpetual. Except for losses related to property damages, the maximum potential amount of future payments the Company could be required to make under these arrangements is unlimited. As of October 2, 2020, the Company had not incurred any significant costs to defend lawsuits or settle claims related to these indemnification arrangements. As a result, the Company believes the estimated fair value of these arrangements is minimal.
VMS has entered into indemnification agreements with its directors and officers and certain of its employees that serve as officers or directors of its foreign subsidiaries that may require VMS to indemnify its directors and officers and those certain employees against liabilities that may arise by reason of their status or service as directors or officers, and to advance their expenses incurred as a result of any legal proceeding against them as to which they could be indemnified.
Product Warranty
The following table reflects the changes in the Company’s accrued product warranty:
 Fiscal Years
(In millions)20202019
Accrued product warranty, at beginning of period$43.2 $44.8 
Charged to cost of revenues58.6 54.2 
Actual product warranty expenditures(62.9)(55.8)
Accrued product warranty, at end of period$38.9 $43.2 
The long-term portion of accrued product warranty costs were $3.5 million and $3.2 million at October 2, 2020, and September 27, 2019, respectively and was included in other long-term liabilities on the Consolidated Balance Sheets.

Leases
The Company leases its facilities and certain equipment under operating leases. The Company's operating leases have remaining lease terms ranging from less than one year to 20 years. Facilities primarily include general and administrative office space, and space for manufacturing, research and development, and other services. Equipment primarily includes vehicles and various office equipment. The Company's finance leases primarily relate to its sale and leaseback-subleases arrangements for certain equipment and have remaining lease terms ranging from one year to seven years.

Lease cost for operating leases is recognized on a straight-line basis over the lease term. Lease cost for finance leases is recognized as amortization of the finance lease ROU asset and interest expense on the finance lease liability over the lease term. The Company also has variable lease cost that primarily relate to its operating leases and include common area maintenance, utilities, maintenance charges, property taxes, insurance, and contingent rent.
The following table summarizes the components of the Company's lease cost:
Twelve Months Ended
(In millions)October 2, 2020
Operating lease cost$31.8 
Finance lease cost:
Amortization of right-of-use assets0.7 
Interest on lease liabilities0.5 
Variable lease cost16.5 
Total lease cost$49.5 

The following table summarizes the supplemental cash flow information related to the Company's operating leases:
Twelve Months Ended
(In millions)October 2, 2020
Cash paid for amounts included in the measurement of lease liabilities:
   Operating cash flows for leases$33.0 

The following table summarizes the supplemental balance sheet information related to the Company's operating and finance leases:
(In millions)October 2, 2020
Operating leases:
Operating right-of-use assets$121.0 
Accrued liabilities$27.2 
Long-term lease liabilities101.1 
   Total lease liabilities$128.3 
Finance leases:
Property, plant, and equipment, net$11.5 
Accrued liabilities$3.4 
Other long-term liabilities8.7 
Total lease liabilities$12.1 
The following table summarizes the weighted lease term and discount rate by operating and finance leases:
October 2, 2020
Weighted average remaining lease term in years
Operating leases7.2
Finance leases4.2
Weighted average discount rate
Operating leases5.0 %
Finance leases3.9 %

As of October 2, 2020, the future minimum lease payments are as follows:
(In millions)Operating LeasesFinance leases
2021$31.7 $3.8 
202226.3 3.1
202321.5 3.1
202415.8 1.2
202512.7 0.8
Thereafter56.2 1.1
  Total minimum lease payments$164.2 $13.1 
Less: imputed interest35.9 1.0 
Total lease liability$128.3 $12.1 

At September 27, 2019, the Company was committed to minimum rentals under non-cancellable operating leases (including rent escalation clauses) for fiscal years 2020 through 2024 and thereafter, as determined under the prior accounting guidance of Accounting Standard Codification 840, as follows: $32.5 million, $26.3 million, $20.2 million, $14.5 million, $10.9 million, and $49.9 million, respectively.
Lessor Arrangements
The Company leases some of its equipment to certain customers on operating leases generally over a period of 16 years. As of October 2, 2020, the Company had $26.5 million and $9.1 million included in property, plant and equipment and accumulated depreciation, respectively, related to equipment leased to customers. As of September 27, 2019, the Company had $22.5 million and $5.5 million included in property, plant and equipment and accumulated depreciation, respectively, related to equipment leased to customers. The Company recorded income on these equipment leases of $9.4 million, $8.8 million and $3.8 million during fiscal years ended October 2, 2020, September 27, 2019 and September 28, 2018, respectively.
Purchase Obligations
At October 2, 2020, the Company was committed to purchase obligations to purchase goods or services that are enforceable, are legally binding and non-cancellable. The Company's purchase obligations for fiscal years 2021 through 2025, are as follows: $88.9 million, $50.8 million, $24.3 million, $20.2 million, and $11.6 million respectively.
Contingencies
Environmental Remediation Liabilities
The Company’s operations and facilities, past and present, are subject to environmental laws, including laws that regulate the handling, storage, transport and disposal of hazardous substances. Certain of those laws impose cleanup liabilities on the Company in connection with its past and present operations. Those include facilities sold as part of the Company’s electron devices business in 1995 and thin film systems business in 1997. As a result, the Company oversees various environmental cleanup projects and receives reimbursements from third parties for a portion of the costs of its cleanup activities.
The Company also reimburses certain third parties for cleanup activities. The amount the Company spent (net of amounts borne by third parties) on environmental cleanup costs, third-party claim costs, project management costs and legal costs during fiscal years 2020, 2019 and 2018, was not material.

With respect to some of these facilities, inherent uncertainties make it difficult to estimate the likelihood of the cost of future cleanup, third-party claims, project management and legal services for the cleanup sites (“Group A Sites”). Nonetheless, as of October 2, 2020, the Company estimated that, net of third parties' indemnification obligations, future costs associated with environmental remediation liabilities for the Group A Sites would range in total from $0.5 million to $3.9 million. The time frames over which these cleanup project costs are estimated vary, ranging from one year up to thirty years as of October 2, 2020. Management believes that no amount in that range is more probable of being incurred than any other amount and therefore had accrued $0.5 million for these cleanup projects as of October 2, 2020. The accrued amount has not been discounted to present value due to the uncertainties that make it difficult to develop a single best estimate.
In addition to the Group A Sites, there are other past and present facilities (“Group B Sites”) where the Company believes it has gained sufficient knowledge to better estimate the scope and cost of monitoring, cleanup and management activities. This, in part, is based on agreements with other parties and also cleanup plans approved by or completed in accordance with the requirements of the governmental agencies having jurisdiction. As of October 2, 2020, the Company estimated that the Company’s future exposure on the Group B Sites, net of third parties' indemnification obligations, for the costs at these facilities, and reimbursements of third-party’s claims for these facilities, ranged in total from $3.1 million to $21.3 million. The time frames over which these costs are estimated to be incurred vary, ranging from zero to thirty years as of October 2, 2020. As to each of these facilities, management determined that a particular amount within the range of estimated costs was a better estimate than any other amount within the range, and that the amount and timing of these future costs were reliably determinable. The best estimate within that range was $3.8 million at October 2, 2020. Accordingly, the Company had accrued $3.5 million for these costs as of October 2, 2020, which represented the best estimate discounted at 4%, net of inflation. This accrual is in addition to the $0.5 million described for the Group A Sites.
 
The table that follows presents information about the Company’s liabilities for future environmental costs at October 2, 2020, based on estimates as of that date.
(In millions)Recurring
Costs
Non-Recurring
Costs
Total
Anticipated
Future Costs
Fiscal Years:   
2021$0.5 $0.5 $1.0 
20220.3 0.2 0.5 
20230.3 0.1 0.4 
20240.3 0.1 0.4 
20250.4 0.9 1.3 
Thereafter0.4 0.3 0.7 
Total costs$2.2 $2.1 $4.3 
Less imputed interest0.3 
Reserve amount$4.0 
Recurring costs include expenses for such tasks as the ongoing operation, maintenance and monitoring of cleanup. Non-recurring costs include expenses for such tasks as soil excavation and treatment, installation of injection and monitoring wells, other costs for soil and groundwater treatment by injection, construction of ground and surface water treatment systems, soil and groundwater investigation, governmental agency costs required to be reimbursed by the Company, removal and closure of treatment systems and monitoring wells, and the defense and settlement of pending and anticipated third-party claims.
These amounts are only estimates of anticipated future costs. The amounts the Company will actually spend may be greater than these estimates. The Company believes its reserve is adequate, however as the scope of the Company’s obligations becomes more clearly defined, the Company may modify the reserve, and charge or credit future earnings accordingly. Based on information currently known to management, management believes the costs of these environmental related matters are not reasonably likely to have a material adverse effect on the consolidated financial statements of the Company in any one fiscal year.
The Company evaluates its liability for investigation and cleanup costs in light of the obligations and apparent financial strength of potential third parties and insurance companies to which the Company believes it has rights to indemnity or reimbursement.
The Company has an agreement with an insurance company under which that insurer has agreed to pay a portion of the Company’s past and future environmental related expenditures. Receivables, net of the portion due to third parties who reimburse the Company, from that insurer amounted to $1.0 million and $1.1 million at October 2, 2020 and September 27, 2019, respectively, with the respective current portion included in prepaid expenses and other current assets and the respective noncurrent portion included in other assets on the Consolidated Balance Sheets. The payable portion to that insurer is included in other long-term liabilities on the Consolidated Balance Sheets. The Company believes that this receivable is recoverable, because it is based on a binding, written settlement agreement with an insurance company that appears to be financially viable and who has paid the Company’s claims in the past.
The availability of the indemnities of third parties' will depend upon the future of their financial strength. Given the long-term nature of some of the liabilities, the third parties may be unable to fund the indemnities in the future. It is also possible that a court would disregard this contractual allocation among the parties and require the Company to assume responsibility for obligations allocated to another party, particularly if the other party were to refuse or was unable to pay any of its allocated share. In addition, the Amended and Restated Distribution Agreement dated as of January 14, 1999 and other associated agreements that govern the Spin-offs generally provide that if a court prohibits a company from satisfying its shared indemnification obligations, the indemnification obligations will be shared equally by the two other companies.
Proposed Acquisition by Siemens Healthineers

In connection with the proposed acquisition by Siemens Healthineers in August 2020, the Company expects to incur approximately $110 million in advisory fees that are contingent upon closing the pending acquisition by Siemens Healthineers. The Merger is expected to close in the first half of calendar year 2021, subject to receipt of specified regulatory approvals and other customary closing conditions. On October 15, 2020, VMS' stockholders approved and adopted the Merger Agreement. Under the terms of the Merger Agreement, if the Merger Agreement is terminated by VMS or Siemens Healthineers under certain specified circumstances, a termination fee of $450.0 million in cash may be payable by VMS to Siemens Healthineers. The Merger Agreement also provides that a reverse termination fee of $450.0 million or $925.0 million in cash may be payable by Siemens Healthineers to VMS if the Merger Agreement is terminated by VMS or Siemens Healthineers under certain specified circumstances.
Other Matters
On October 16, 2018, Best Medical International, Inc. sued the Company in U.S. District Court in the District of Delaware, alleging infringement of four patents related to treatment planning. The Company intends to defend the suit vigorously. The suit is in the discovery stage, the parties have completed mediation, and a trial date is currently schedule for April 2022. At October 2, 2020, the Company has accrued $8.5 million representing its best estimate of the loss that may result from this action. The ultimate outcome of this matter is uncertain and may result in a materially different outcome.
From time to time, the Company is a party to or otherwise involved in legal proceedings, claims and government inspections or investigations and other legal matters, both inside and outside the United States, arising in the ordinary course of its business or otherwise. The Company accrues amounts, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss (including, among other things, probable settlement value). A loss or a range of loss is disclosed when it is reasonably possible that a material loss will be incurred and can be estimated or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision. 
In addition to the above, the Company is involved in other legal matters. However, such matters are subject to many uncertainties and their outcomes are not predictable with assurance. The Company is unable to estimate a range of reasonably possible losses with respect to such matters. There can be no assurances as to whether the Company will become subject to significant additional claims and liabilities with respect to ongoing or future proceedings. If actual liabilities significantly exceed the estimates made, the Company’s consolidated financial position, results of operations or cash flows could be materially adversely affected. Legal expenses relating to legal matters are expensed as incurred.
Restructuring Charges

2020 Restructuring Plan
In the third quarter of fiscal year 2020, the Company implemented a global workforce reduction, as part of the Company's plan to enhance operational performance through productivity initiatives in response to the impact of the COVID-19 pandemic. The Company incurred $18.7 million in restructuring charges in the fiscal year 2020, which primarily consisted of employee-related
expenses. The Company paid $12.0 million related to these charges in fiscal year 2020, and the remaining balance of $6.7 million is expected to be paid in fiscal year 2021. The Company expects to incur additional restructuring charges under this plan; however, these costs are not expected to be material. The restructuring charges are included in impairment and restructuring charges in the Consolidated Statements of Earnings.